Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate
Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate
Aytu BioPharma 2024年第二季度GAAP每股收益（0.04美元）超过预期（0.25美元），销售额2,293万美元超过2175万美元的预期
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. The company reported quarterly sales of $22.93 million which beat the analyst consensus estimate of $21.75 million by 5.47 percent. This is a 12.73 percent decrease over sales of $26.28 million the same period last year.
艾图生物制药（纳斯达克股票代码：AYTU）公布的季度亏损为每股0.04美元，比分析师普遍预期的0.25美元（0.25美元）高出84％。该公司公布的季度销售额为2,293万美元，比分析师普遍预期的2175万美元高出5.47％。这比去年同期的2628万美元销售额下降了12.73％。